Research progress of Osimertinib acquired resistance
10.12092/j.issn.1009-2501.2021.01.014
- Author:
Qinghua PEI
1
;
Jianli SUN
1
Author Information
1. No.6 Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
- Publication Type:Journal Article
- Keywords:
Acquired resistance;
Non-small cell lung cancer;
Osimertinib;
Research progress
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2021;26(1):105-112
- CountryChina
- Language:Chinese
-
Abstract:
Osimertinib, as a representative of the third generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has significant curative effect for EGFR T790M mutation type non-small cell lung cancer (NSCLC). But with the development of clinical research Osimertinib's resistance gradually appear. How to deal with the resistance is a problem that the clinical workers must focus on. This article will review the latest research progress of the mechanisms and the solutions of osimertinib acquired resistance.
